Shanghai Degron Raises $22 Million for Protein Degradation Drugs

Shanghai Degron Therapeutics raised $22 million in a Series A round to develop small-molecule medicines that target previously undruggable targets. Degron’s GlueXplorer® platform is based on a unique molecular glue-based targeted protein degradation technology aimed at accelerating the development of novel drugs for oncology, inflammation, metabolic disease and rare diseases. The company has three pipeline programs in lead-optimization, including a first-in-class target with potential application to a broad range of cancers and immune diseases. The funding was led by Med-Fine Capital and included Dyee Capital, Baidu Venture, and NeuX Capital. More details....

Share this with colleagues: